0	11	Association	Association	NNP
12	14	of	of	IN
15	18	the	the	DT
19	32	interleukin-4	interleukin-4	NN
33	41	receptor	receptor	NN
42	47	alpha	alpha	NN
48	53	chain	chain	NN
54	58	with	with	IN
59	66	p47phox	p47phox	NN
66	67	,	,	,
68	70	an	an	DT
71	80	activator	activator	NN
81	83	of	of	IN
84	87	the	the	DT
88	97	phagocyte	phagocyte	NN
98	103	NADPH	nadph	NN
104	111	oxidase	oxidase	NN
112	114	in	in	IN
115	116	B	B	NNP
117	122	cells	cell	NNS
122	123	.	.	.

125	136	Interleukin	Interleukin	NNP
137	138	(	(	(
138	143	IL)-4	il)-4	NN
144	149	plays	play	VBZ
150	152	an	an	DT
153	162	important	important	JJ
163	167	role	role	NN
168	170	in	in	IN
171	174	IgE	ige	NN
175	184	synthesis	synthesis	NN
185	187	in	in	IN
188	189	B	B	NNP
190	195	cells	cell	NNS
196	199	and	and	CC
200	202	in	in	IN
203	206	Th2	th2	NN
207	222	differentiation	differentiation	NN
223	225	in	in	IN
226	227	T	t	NN
228	233	cells	cell	NNS
233	234	.	.	.

235	239	IL-4	il-4	NN
240	248	conducts	conduct	VBZ
249	252	its	its	PRP$
253	263	biological	biological	JJ
264	274	activities	activity	NNS
275	282	through	through	IN
283	290	binding	bind	VBG
291	293	to	to	TO
294	297	the	the	DT
298	302	IL-4	il-4	NN
303	311	receptor	receptor	NN
312	313	(	(	(
313	318	IL-4R	IL-4R	NNP
318	319	)	)	)
320	322	on	on	IN
323	326	the	the	DT
327	334	surface	surface	NN
335	337	of	of	IN
338	344	target	target	NN
345	350	cells	cell	NNS
350	351	.	.	.

352	357	IL-4R	IL-4R	NNP
358	361	are	be	VBP
362	369	thought	think	VBN
370	372	to	to	TO
373	375	be	be	VB
376	384	composed	compose	VBN
385	387	of	of	IN
388	391	the	the	DT
392	397	IL-4R	IL-4R	NNP
398	403	alpha	alpha	NN
404	409	chain	chain	NN
410	411	(	(	(
411	416	IL-4R	IL-4R	NNP
417	422	alpha	alpha	NN
422	423	)	)	)
424	427	and	and	CC
428	434	either	either	CC
435	438	the	the	DT
439	444	IL-2R	IL-2R	NNP
445	450	gamma	gamma	NN
451	456	chain	chain	NN
457	459	or	or	CC
460	463	the	the	DT
464	470	IL-13R	IL-13R	NNP
471	476	alpha	alpha	NN
477	482	chain	chain	NN
482	483	.	.	.

484	486	We	we	PRP
487	491	have	have	VBP
492	502	previously	previously	RB
503	508	shown	show	VBN
509	513	that	that	IN
514	517	the	the	DT
518	535	membrane-proximal	membrane-proximal	JJ
536	543	portion	portion	NN
544	546	in	in	IN
547	550	the	the	DT
551	562	cytoplasmic	cytoplasmic	JJ
563	569	domain	domain	NN
570	572	of	of	IN
573	576	the	the	DT
577	582	human	human	JJ
583	588	IL-4R	il-4r	NN
589	594	alpha	alpha	NN
595	596	(	(	(
596	602	hIL-4R	hIL-4R	NNP
603	608	alpha	alpha	NN
608	609	)	)	)
610	612	is	be	VBZ
613	621	critical	critical	JJ
622	625	for	for	IN
626	639	proliferation	proliferation	NN
639	640	,	,	,
641	651	generation	generation	NN
652	654	of	of	IN
655	663	germline	germline	NN
664	671	epsilon	epsilon	NN
672	682	transcript	transcript	NN
682	683	,	,	,
684	687	and	and	CC
688	698	activation	activation	NN
699	701	of	of	IN
702	707	STAT6	STAT6	NNP
707	708	,	,	,
709	714	based	base	VBN
715	717	on	on	IN
718	726	analyses	analysis	NNS
727	729	of	of	IN
730	739	truncated	truncate	VBN
740	746	hIL-4R	hIL-4R	NNP
747	753	alphas	alpha	NNS
753	754	.	.	.

755	757	In	in	IN
758	762	this	this	DT
763	768	study	study	NN
768	769	,	,	,
770	772	we	we	PRP
773	778	found	find	VBD
779	783	that	that	IN
784	791	p47phox	p47phox	NN
791	792	,	,	,
793	795	an	an	DT
796	805	activator	activator	NN
806	808	of	of	IN
809	812	the	the	DT
813	822	phagocyte	phagocyte	NN
823	828	NADPH	nadph	NN
829	836	oxidase	oxidase	NN
836	837	,	,	,
838	843	binds	bind	VBZ
844	846	to	to	TO
847	851	this	this	DT
852	859	portion	portion	NN
860	862	by	by	IN
863	866	the	the	DT
867	877	two-hybrid	two-hybrid	JJ
878	884	system	system	NN
884	885	.	.	.

886	897	Furthermore	furthermore	RB
897	898	,	,	,
899	901	we	we	PRP
902	910	observed	observe	VBD
911	914	the	the	DT
915	926	association	association	NN
927	929	of	of	IN
930	937	p47phox	p47phox	NN
938	942	with	with	IN
943	946	the	the	DT
947	953	hIL-4R	hIL-4R	NNP
954	959	alpha	alpha	NN
960	962	in	in	IN
963	964	B	B	NNP
965	970	cells	cell	NNS
971	978	derived	derive	VBN
979	983	from	from	IN
984	985	a	a	DT
986	992	normal	normal	JJ
993	998	donor	donor	NN
998	999	.	.	.

1000	1005	These	these	DT
1006	1013	results	result	NNS
1014	1021	suggest	suggest	VBP
1022	1026	that	that	IN
1027	1034	p47phox	p47phox	NN
1035	1037	is	be	VBZ
1038	1046	involved	involve	VBN
1047	1049	in	in	IN
1050	1053	the	the	DT
1054	1060	signal	signal	NN
1061	1073	transduction	transduction	NN
1074	1076	of	of	IN
1077	1081	IL-4	il-4	NN
1082	1084	in	in	IN
1085	1086	B	B	NNP
1087	1092	cells	cell	NNS
1092	1093	.	.	.

1094	1101	However	however	RB
1101	1102	,	,	,
1103	1113	activation	activation	NN
1114	1116	of	of	IN
1117	1122	STAT6	STAT6	NNP
1122	1123	,	,	,
1124	1128	CD23	cd23	NN
1129	1139	expression	expression	NN
1139	1140	,	,	,
1141	1144	and	and	CC
1145	1148	IgE	IgE	NNP
1149	1158	synthesis	synthesis	NN
1159	1166	induced	induce	VBN
1167	1169	by	by	IN
1170	1174	IL-4	il-4	NN
1175	1179	were	be	VBD
1180	1183	not	not	RB
1184	1192	affected	affect	VBN
1193	1195	in	in	IN
1196	1213	p47phox-deficient	p47phox-deficient	JJ
1214	1222	patients	patient	NNS
1222	1223	,	,	,
1224	1229	which	which	WDT
1230	1236	raises	raise	VBZ
1237	1240	the	the	DT
1241	1252	possibility	possibility	NN
1253	1257	that	that	IN
1258	1265	p47phox	p47phox	NN
1266	1269	may	may	MD
1270	1272	be	be	VB
1273	1282	important	important	JJ
1283	1285	in	in	IN
1286	1291	other	other	JJ
1292	1301	signaling	signaling	NN
1302	1312	activities	activity	NNS
1313	1315	as	as	RB
1316	1320	well	well	RB
1321	1323	in	in	IN
1324	1325	B	B	NNP
1326	1331	cells	cell	NNS
1331	1332	.	.	.